Skip to content

Study of Shatavari Root Extract on Breast Milk Production in Postpartum Women

Effects of Shatavari (Asparagus racemosus) Root Extract 6-Weeks Therapy on Lactation in Post-partum Women: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/05/111375
Enrollment
100
Registered
2026-05-29
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O923- Agalactia

Interventions

None listed

Sponsors

Ixoreal Biomed Private Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Healthy women between 20-40 years of age 2.Women with uncomplicated full-term delivery (vaginal or LSCS). 3.Women who have accomplished antenatal breastfeeding promotion protocol immediately postpartum or within three days of delivery. 4.Women able to understand the study requirements and can fill the study log diary, and follow other procedures required by the study protocol. 5.Must have the ability and willingness to sign an informed consent and to comply with all study procedures.

Exclusion criteria

Exclusion criteria: 1.Postpartum women with contraindications to breastfeeding, such as HIV, chemotherapeutic drugs, radioactive substances, and babies with galactosemia. 2.Postpartum women with unstable conditions (i.e., postpartum hemorrhage, sepsis). 3.Women with known allergies to Shatavari or oats, raisins, almonds, cocoa, and honey. 4.Women whose babies require phototherapy, women with insufficient glandular tissue or breast surgery and any structural abnormality of the breast. 5.Women with a history of infertility, hypothyroidism, women with twins, or higher-order births. 6.Any known clinically significant endocrine, metabolic, hepatic, renal, cardiovascular, gastrointestinal, respiratory, hematological, or neurological illnesses or the presence of any current psychiatric disorders in women will be considered as exclusion criteria.

Design outcomes

Primary

MeasureTime frame
Total volume (mL) of breast milk extracted by breast pump (manual/automatic)Timepoint: Baseline, 72 hrs., Week 2, Week 4, Week 6

Secondary

MeasureTime frame
Time (hours) to first evident noticeable breast fullness after deliveryTimepoint: Delivery to 72 hrs;Time (hours) to noticeable breast fullness after last feeding based on maternal perception recorded in diaryTimepoint: Week 2, Week 4, Week 6;Breastfeeding Self Efficacy Scale Short Form (BSES SF) scoresTimepoint: Day 3 (72 hours), Week 2, Week 4, Week 6;Frequency of breastfeeding/feeding sessions per 24 hours; documented in maternal diaryTimepoint: Week 2, Week 4, Week 6;Mean Edinburgh Postnatal Depression Scale (EPDS) scores; maternal psychological well being assessmentTimepoint: Day 3 (72 hours), Week 2, Week 4, Week 6;Nipple pain or trauma evaluated using Visual Analog Scale (VAS 0 10)Timepoint: Day 3 (72 hrs.), Week 2, Week 4, Week 6;Mean change in Infant body weight (weight gain) from birthTimepoint: Delivery, Day 3 (72 hrs.), Week 2, Week 4, Week 6;Infant outcomes including fussiness and stooling frequency; documented in maternal diaryTimepoint: Day 3 (72 hrs.), Week 2, Week 4, Week 6;Detection of Shatavari in breast milk samples in a subset of 5 10 participantsTimepoint: Week 2, Week 4, Week 6

Countries

India

Contacts

Public ContactDr Hemant Mandlik

Sukhakarta Hospital

drhemantmandlik05@gmail.com7620691852

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026